Loading
A phase 1/2 trial of HH2853 Tablets in peripheral T-cell lymphomas, run by Haihe Biopharma Co., Ltd., now recruiting.
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma is a phase 1/2 interventional study registered as NCT06909877 by Haihe Biopharma Co., Ltd., with 100 participants planned, started 2022-07-27 and due to reach its primary completion in 2025-10-31. Interventions recorded: HH2853 Tablets.
Shares Haihe Biopharma, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Haihe Biopharma and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.